Rapid and successful drug development has resulted in multiple treatment options for advanced prostate cancer that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that are also costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, molecular characterization, and genetic assays have led to many open questions and areas for which there is sparse or low-level evidence to support clinical decision-making.

The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer, with a special focus on these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions, and debates to summarize and conceptualize the available literature and evidence.

More than 100 of the world’s leading experts will form the consensus panel in 2024. They will also participate as moderators and or speakers in the conference programme. Following the conference, a manuscript with these expert recommendations is published in European Urology. See Publications here

Aims of APCCC

• Provide an update on the current advanced prostate cancer management standard, focusing on situations with no high-level evidence for a specific treatment option.
• APCCC defines advanced prostate cancer as locally advanced disease, biochemical recurrence, and metastatic disease.
• Offer a highly educational program consisting of invited lectures, debates, and discussions led by a panel of international and interdisciplinary prostate cancer experts.
• Translate knowledge by summarising and conceptualizing current standards of advanced prostate cancer management and disseminating the results of consensus discussions and voting.
• During the meeting, convene these experts to discuss predefined questions regarding key areas of debate or lack of evidence regarding the optimal treatment of men with advanced prostate cancer. The conference and the development of these questions have been described in detail (see APCCC 2015, APCCC 2017, APCCC 2019, APCCC 2021, and APCCC 2022).
• After the meeting, publish the consensus summary in a high-impact medical journal.
• Conference attendees can participate in the two days of discussions and the consensus panel discussion. Attendees are encouraged to interact with panel members to facilitate and promote international collaboration.